Literature DB >> 25394175

A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.

Heather Hampel1, Robin L Bennett2, Adam Buchanan3, Rachel Pearlman1, Georgia L Wiesner4.   

Abstract

DISCLAIMER: The practice guidelines of the American College of Medical Genetics and Genomics (ACMG) and the National Society of Genetic Counselors (NSGC) are developed by members of the ACMG and NSGC to assist medical geneticists, genetic counselors, and other health-care providers in making decisions about appropriate management of genetic concerns, including access to and/or delivery of services. Each practice guideline focuses on a clinical or practice-based issue and is the result of a review and analysis of current professional literature believed to be reliable. As such, information and recommendations within the ACMG and NSGC joint practice guidelines reflect the current scientific and clinical knowledge at the time of publication, are current only as of their publication date, and are subject to change without notice as advances emerge. In addition, variations in practice, which take into account the needs of the individual patient and the resources and limitations unique to the institution or type of practice, may warrant approaches, treatments, and/or procedures that differ from the recommendations outlined in this guideline. Therefore, these recommendations should not be construed as dictating an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. Genetic counseling practice guidelines are never intended to displace a health-care provider's best medical judgment based on the clinical circumstances of a particular patient or patient population. Practice guidelines are published by the ACMG or the NSGC for educational and informational purposes only, and neither the ACMG nor the NSGC "approve" or "endorse" any specific methods, practices, or sources of information.Cancer genetic consultation is an important aspect of the care of individuals at increased risk of a hereditary cancer syndrome. Yet several patient, clinician, and system-level barriers hinder identification of individuals appropriate for cancer genetics referral. Thus, the purpose of this practice guideline is to present a single set of comprehensive personal and family history criteria to facilitate identification and maximize appropriate referral of at-risk individuals for cancer genetic consultation. To develop this guideline, a literature search for hereditary cancer susceptibility syndromes was conducted using PubMed. In addition, GeneReviews and the National Comprehensive Cancer Network guidelines were reviewed when applicable. When conflicting guidelines were identified, the evidence was ranked as follows: position papers from national and professional organizations ranked highest, followed by consortium guidelines, and then peer-reviewed publications from single institutions. The criteria for cancer genetic consultation referral are provided in two formats: (i) tables that list the tumor type along with the criteria that, if met, would warrant a referral for a cancer genetic consultation and (ii) an alphabetical list of the syndromes, including a brief summary of each and the rationale for the referral criteria that were selected. Consider referral for a cancer genetic consultation if your patient or any of their first-degree relatives meet any of these referral criteria.

Entities:  

Mesh:

Year:  2014        PMID: 25394175     DOI: 10.1038/gim.2014.147

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  173 in total

1.  American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing.

Authors: 
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 2.  Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature.

Authors:  M H Nieuwenhuis; H F A Vasen
Journal:  Crit Rev Oncol Hematol       Date:  2006-10-24       Impact factor: 6.312

Review 3.  Hereditary prostate cancer: epidemiologic and clinical features.

Authors:  B S Carter; G S Bova; T H Beaty; G D Steinberg; B Childs; W B Isaacs; P C Walsh
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

4.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.

Authors:  Katherine A Janeway; Su Young Kim; Maya Lodish; Vânia Nosé; Pierre Rustin; José Gaal; Patricia L M Dahia; Bernadette Liegl; Evan R Ball; Margarita Raygada; Angela H Lai; Lorna Kelly; Jason L Hornick; Maureen O'Sullivan; Ronald R de Krijger; Winand N M Dinjens; George D Demetri; Cristina R Antonescu; Jonathan A Fletcher; Lee Helman; Constantine A Stratakis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

5.  Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma.

Authors:  T Kivelä
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

Review 6.  Thyroid cancer genetics: multiple endocrine neoplasia type 2, non-medullary familial thyroid cancer, and familial syndromes associated with thyroid cancer.

Authors:  Melanie L Richards
Journal:  Surg Oncol Clin N Am       Date:  2009-01       Impact factor: 3.495

7.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

Authors:  J P Struewing; D Abeliovich; T Peretz; N Avishai; M M Kaback; F S Collins; L C Brody
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

8.  High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.

Authors:  Virginie Bubien; Françoise Bonnet; Veronique Brouste; Stéphanie Hoppe; Emmanuelle Barouk-Simonet; Albert David; Patrick Edery; Armand Bottani; Valérie Layet; Olivier Caron; Brigitte Gilbert-Dussardier; Capucine Delnatte; Catherine Dugast; Jean-Pierre Fricker; Dominique Bonneau; Nicolas Sevenet; Michel Longy; Frédéric Caux
Journal:  J Med Genet       Date:  2013-01-18       Impact factor: 6.318

9.  MEN1 gene analysis in patients with primary hyperparathyroidism: 10-year experience of a single institution for thyroid and parathyroid care in Japan.

Authors:  Minoru Kihara; Akira Miyauchi; Yasuhiro Ito; Hiroshi Yoshida; Akihiro Miya; Kaoru Kobayashi; Yuuki Takamura; Mitsuhiro Fukushima; Hiroyuki Inoue; Takuya Higashiyama; Chisato Tomoda
Journal:  Endocr J       Date:  2009-05-20       Impact factor: 2.349

10.  Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1.

Authors:  Emma Jaeger; Simon Leedham; Annabelle Lewis; Stefania Segditsas; Martin Becker; Pedro Rodenas Cuadrado; Hayley Davis; Kulvinder Kaur; Karl Heinimann; Kimberley Howarth; James East; Jenny Taylor; Huw Thomas; Ian Tomlinson
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

View more
  134 in total

Review 1.  Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.

Authors:  Toshifumi Wakai; Pankaj Prasoon; Yuki Hirose; Yoshifumi Shimada; Hiroshi Ichikawa; Masayuki Nagahashi
Journal:  Int J Clin Oncol       Date:  2018-12-04       Impact factor: 3.402

Review 2.  Survivorship Guidance for Patients with Colorectal Cancer.

Authors:  Jillian Simard; Suneel Kamath; Sheetal Kircher
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

Review 3.  A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.

Authors:  Brian T Helfand; Carly A Conran; Jianfeng Xu; William J Catalona
Journal:  Curr Opin Urol       Date:  2017-09       Impact factor: 2.309

4.  A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.

Authors:  Erica M Bednar; Holly D Oakley; Charlotte C Sun; Catherine C Burke; Mark F Munsell; Shannon N Westin; Karen H Lu
Journal:  Gynecol Oncol       Date:  2017-06-10       Impact factor: 5.482

5.  A model for patient-direct screening and referral for familial cancer risk.

Authors:  Kristin B Niendorf; Melissa A Geller; Rachel Isaksson Vogel; Timothy R Church; Anna Leininger; Angela Bakke; Robert D Madoff
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

Review 6.  Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?

Authors:  Lauren Fishbein
Journal:  Curr Cardiol Rep       Date:  2019-07-31       Impact factor: 2.931

Review 7.  Getting personal: Head and neck cancer management in the era of genomic medicine.

Authors:  Andrew C Birkeland; Wendy R Uhlmann; J Chad Brenner; Andrew G Shuman
Journal:  Head Neck       Date:  2015-08-13       Impact factor: 3.147

8.  Germline mutations in hereditary diffuse gastric cancer.

Authors:  Hao Zhang; Mengmeng Feng; Yi Feng; Zhaode Bu; Ziyu Li; Shuqin Jia; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

9.  The Influence of Adolescence on Parents' Perspectives of Testing and Discussing Inherited Cancer Predisposition.

Authors:  Corinna L Schultz; Melissa A Alderfer; Robert B Lindell; Zachary McClain; Kristin Zelley; Kim E Nichols; Carol A Ford
Journal:  J Genet Couns       Date:  2018-06-16       Impact factor: 2.537

10.  Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin.

Authors:  Bridget K Marcellino; Noushin Farnoud; Bruno Cassinat; Min Lu; Emanuelle Verger; Erin McGovern; Minal Patel; Juan Medina-Martinez; Max Fine Levine; Juanes E Arango Ossa; Yangyu Zhou; Heidi Kosiorek; Meenakshi Mehrotra; Jane Houldsworth; Amylou Dueck; Michael Rossi; John Mascarenhas; Jean-Jacques Kiladjian; Raajit K Rampal; Ronald Hoffman
Journal:  Blood Adv       Date:  2020-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.